Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

European Society of Cardiology Congress 2016

Rome, Italy
27-31 August 2016

ESC Poster news: Long-term data with evolocumab in heterozygous FH

ESC Poster news: Long-term data with evolocumab in heterozygous FH

30th August 2016, Rome, Italy Evolocumab was effective and well tolerated in patients with heterozygous familial hypercholesterolaemia (FH, inherited high cholesterol) treated for up to 48 weeks (1). Previously, the RUTHEFORD studies in heterozygous FH showed that evolocumab given for 12 weeks was effective in…

read more »
ESC Poster news: Consistent benefit with evolocumab in high and very high risk patients

ESC Poster news: Consistent benefit with evolocumab in high and very high risk patients

30th August 2016, Rome, Italy In a pooled analysis of more than 2500 patients, the LDL cholesterol lowering efficacy of evolocumab was consistent in both very high risk and high risk patients (1). The 2016 European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) guidelines categorise…

read more »
ESC Poster news: More reassurance on alirocumab safety at very low LDL cholesterol

ESC Poster news: More reassurance on alirocumab safety at very low LDL cholesterol

30th August 2016, Rome, Italy In an updated safety analysis for alirocumab treatment for up to 104 weeks, there was no evidence of any safety issues affecting neurological or neurocognitive function with alirocumab (1). Data were pooled from 14 Phase II and III trials, comprising…

read more »
ESC Poster news: Alirocumab effective in patients with multiple manifestations of cardiovascular disease

ESC Poster news: Alirocumab effective in patients with multiple manifestations of cardiovascular disease

30th August 2016, Rome, Italy Alirocumab, was effective and well tolerated in patients with multiple manifestations of cardiovascular disease receiving statins with or without other lipid lowering therapy, according to a post hoc analysis of the ODYSSEY trials (1). The investigators evaluated data from patients…

read more »
PCSK9 inhibition reduces the need for lipoprotein apheresis in severe heterozygous familial hypercholesterolaemia patients

PCSK9 inhibition reduces the need for lipoprotein apheresis in severe heterozygous familial hypercholesterolaemia patients

ESC Congress, Rome, 29 August 2016 Results from this Monday Hotline of the ODYSSEY ESCAPE study show that treatment with the PCSK9 monoclonal antibody alirocumab reduces the frequency of lipoprotein apheresis in patients with heterozygous familial hypercholesterolaemia (FH, inherited high cholesterol) requiring this therapy. At…

read more »
PlayODYSSEY ESCAPE: a view from PCSK9 Forum

ODYSSEY ESCAPE: a view from PCSK9 Forum

PCSK9 Forum News Editor, Dr Peter Lansberg (Amsterdam Medical Center, the Netherlands) discusses ODYSSEY ESCAPE and the implications for the management of heterozygous familial hypercholesterlaemia patients with severely elevated LDL cholesterol levels despite maximal LDL lowering therapy.

read more »